In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

For the last decade, Erin D. Michos, MD (Johns Hopkins University School of Medicine, Baltimore, MD), has consistently posted updates to her feed on X (formerly Twitter) for her more than 30,000 ...

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.